Allergan Signals Higher Prices Potentially Ahead for Teva Pharmaceuticals
Teva Pharmaceuticals (TEVA) lost 24% last Thursday after reporting disappointing earnings. From the Seeking Alpha transcript of the conference call: “All of us at Teva understand the frustration and disappointment our shareholders are feeling… In our U.S. Generics business, we experienced accelerated price erosion and decreased volume, mainly due to customer consolidation, greater competition as … Read more